The effect of Crohn's disease on outcomes after total hip arthroplasty

Andrew J Hinkle1, Hunter B Jones1, Vikram A Aggarwal2

  • 1Department of Orthopedics, University of Texas Southwestern, Dallas, TX, USA.

Insights

Patients with Crohn's disease (CD) undergoing total hip arthroplasty (THA) experienced longer hospital stays and higher complication rates compared to those without CD. This highlights the need for tailored surgical planning and care for CD patients.

Area of Science:

  • Orthopedics
  • Gastroenterology
  • Health Services Research

Background:

  • Crohn's disease (CD) incidence is rising globally, with significant musculoskeletal impacts like arthritis.
  • Large joint arthritis is a common manifestation, necessitating interventions like total hip arthroplasty (THA).

Purpose of the Study:

  • To compare post-operative length of stay, healthcare costs, and complication rates in patients with and without Crohn's Disease (CD) undergoing THA.
  • To identify specific risks and outcomes associated with THA in CD patients.

Main Methods:

  • Utilized data from the National Inpatient Sample Database (2016-2019).
  • Identified patients with CD and without CD (NCD) undergoing THA using ICD-10 codes.
  • Compared length of stay, total cost, and medical/surgical complications between CD and NCD cohorts using SPSS.

Main Results:

  • Included 1,171 CD patients and 366,219 NCD patients.
  • CD patients were younger, more likely Caucasian, non-obese, and non-emergently admitted.
  • CD patients had significantly longer lengths of stay (p < 0.001) and higher risks of acute renal failure, anemia, blood transfusion, pneumonia, DVT, and periprosthetic infection.
  • CD patients showed a lower risk of periprosthetic mechanical complications (OR=0.218, p=0.011).

Conclusions:

  • CD patients undergoing THA present with younger demographics, extended hospital stays, and increased local and systemic complication rates compared to NCD patients.
  • Findings support enhanced surgical candidate selection and operative planning for CD patients.
  • Further research into the mechanisms driving these outcome disparities is recommended to advance orthopedic care for CD patients.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
111
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
134
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
70